Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Eloy E. Ordaya"'
Publikováno v:
JAAD Case Reports, Vol 40, Iss , Pp 132-135 (2023)
Externí odkaz:
https://doaj.org/article/807de44495f049aa8b8a0c3752fe0228
Publikováno v:
IDCases, Vol 27, Iss , Pp e01392- (2022)
Externí odkaz:
https://doaj.org/article/a556a9093adb4d4fbec3538b4f359eaa
Autor:
Qiaonan Zhong, Eloy E. Ordaya, Santiago Delgado Fernandez, Kristin Lescalleet, Daniel Larson, Bobbi Pritt, Elie Berbari
Publikováno v:
IDCases, Vol 29, Iss , Pp e01603- (2022)
Histoplasmosis commonly presents as an asymptomatic or self-limited infection in immunocompetent patients, but immunocompromised hosts may present with severe and disseminated disease. Herein, we present a 26-year-old male with history of ulcerative
Externí odkaz:
https://doaj.org/article/fc0c27126d11447f84c436b8e467fba2
Publikováno v:
Open Forum Infectious Diseases.
Patients with blood culture-negative endocarditis due to Bartonella infection frequently had prosthetic cardiac valves, and presented with fever, cytopenias, and kidney failure associated with ANCA PR3 positivity. Patients had a wide range of Bartone
Autor:
Eloy E. Ordaya, Megan Shaughnessy, Baila Elkin, Rachel L. Husmann, Jacob C. Stauffer, Elizabeth M. Luengas, Bickey H. Chang, Katelyn M. Tessier, Patricia F. Walker, William M. Stauffer
Publikováno v:
Transplant Infectious Disease. 25
Publikováno v:
Mayo Clinic Proceedings
Publikováno v:
Transplant Infectious Disease.
Autor:
Eloy E Ordaya, Omar M Abu Saleh, Paschalis Vergidis, Sharon Deml, Nancy Wengenack, Madiha Fida
Publikováno v:
Open Forum Infectious Diseases. 9
Background There are not established clinical breakpoints (CBP) for antifungals against Cryptococcus species; However, the analysis of their MICs using epidemiological cut-off values (ECVs) can help to distinguish wild-type (WT) isolates from non-WT
Publikováno v:
Open Forum Infectious Diseases. 9
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevi
Publikováno v:
Journal of Clinical Virology. 160:105382